BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 27889629)

  • 1. Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.
    Qin JM; Huang RZ; Yao GY; Liao ZX; Pan YM; Wang HS
    Eur J Med Chem; 2017 Jan; 126():259-269. PubMed ID: 27889629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
    Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M
    J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome.
    Hsu HC; Singh PK; Fan H; Wang R; Sukenick G; Nathan C; Lin G; Li H
    Biochemistry; 2017 Jan; 56(1):324-333. PubMed ID: 27976853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
    Zhuang R; Gao L; Lv X; Xi J; Sheng L; Zhao Y; He R; Hu X; Shao Y; Pan X; Liu S; Huang W; Zhou Y; Li J; Zhang J
    Eur J Med Chem; 2017 Jan; 126():1056-1070. PubMed ID: 28027531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
    Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
    Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
    Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
    Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
    Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
    ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides.
    Zhan W; Singh PK; Ban Y; Qing X; Ah Kioon MD; Fan H; Zhao Q; Wang R; Sukenick G; Salmon J; Warren JD; Ma X; Barrat FJ; Nathan CF; Lin G
    J Med Chem; 2020 Nov; 63(21):13103-13123. PubMed ID: 33095579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening.
    Di Giovanni C; Ettari R; Sarno S; Rotondo A; Bitto A; Squadrito F; Altavilla D; Schirmeister T; Novellino E; Grasso S; Zappalà M; Lavecchia A
    Eur J Med Chem; 2016 Oct; 121():578-591. PubMed ID: 27318981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of dipeptides as novel non-covalent 20S proteasome inhibitors.
    Yang YJ; Wang K; Yang Y; Lai FF; Chen XG; Xiao ZY
    J Asian Nat Prod Res; 2021 May; 23(5):436-451. PubMed ID: 33844614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
    Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
    Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
    Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
    Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and activity of tyropeptin A derivatives as potent and selective inhibitors of mammalian 20S proteasome.
    Momose I; Umezawa Y; Hirosawa S; Iijima M; Iinuma H; Ikeda D
    Biosci Biotechnol Biochem; 2005 Sep; 69(9):1733-42. PubMed ID: 16195592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Side chain-functionalized aniline-derived ursolic acid derivatives as multidrug resistance reversers that block the nuclear factor-kappa B (NF-κB) pathway and cell proliferation.
    Huang RZ; Hua SX; Liao ZX; Huang XC; Wang HS
    Medchemcomm; 2017 Jul; 8(7):1421-1434. PubMed ID: 30108853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
    Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
    Zhao Y; Xu L; Zhang J; Zhang M; Lu J; He R; Xi J; Zhuang R; Li J; Zhou Y
    Bioorg Med Chem; 2021 Jan; 29():115867. PubMed ID: 33223460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenoxypropanolamine derivatives as selective inhibitors of the 20S proteasome β1 and β5 subunits.
    Hovhannisyan AA; Pham TH; Bouvier D; Tan X; Touhar S; Mkryan GG; Dallakyan AM; El Amri C; Melikyan GS; Reboud-Ravaux M; Bouvier-Durand M
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5172-5178. PubMed ID: 29113763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
    Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
    Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
    Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R
    Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.